Mnatzaganian Christina, Bounthavong Mark, Abalos Wendelle, Chau Truc, Nwosu Oluchi, Yi Andrew, Saunders Ila, Kelly Panteha
J Am Pharm Assoc (2003). 2025 Jul-Aug;65(4):102397. doi: 10.1016/j.japh.2025.102397. Epub 2025 Apr 4.
There is limited but positive evidence of the impact of pharmacists in managing patients with type 2 diabetes (T2D) using a personal continuous glucose monitor (CGM). Previous studies have been limited to single clinic pilots or community pharmacies with small sample sizes.
To evaluate the impact on glycemic outcomes of an innovative pharmacist-led Diabetes Management and Education Clinic (DMEC) on patients with T2D using a personal CGM.
The DMEC operates in primary care settings in a large, tertiary academic health care system serving a large patient population. Pharmacists manage care for patients with T2D who are referred by primary care and specialty medical providers under a collaborative practice agreement.
To use CGM data to guide decision making for clinical pharmacists seeing patients with T2D in the DMEC.
This was a retrospective study conducted at the DMEC over 2 years. Demographics and glycemic outcomes were collected from the electronic medical record for patients who had a personal CGM prior to the initial clinic visit, supplied during the visit, or ordered as a prescription. A descriptive analysis was completed for this study.
DMEC pharmacists used CGMs to guide treatment decisions for 165 patients. The average hemoglobin A1c decreased by 1.48% at 3 months (P < 0.001) and 1.74% at 6 months (P < 0.001) after initial visit. Time in range improved by 8.2% at 3 months (P < 0.001) and by 12.1% at 6 months (P < 0.001). The glucose management indicator decreased by 0.27% at 3 months (P < 0.001) and 0.53% at 6 months (P < 0.001). The average glucose decreased by 13.5 mg/dL at 3 months (P < 0.001) and 18.8 mg/dL at 6 months (P < 0.001).
Pharmacist-led management of T2D using personal CGMs can improve diabetes outcomes in a large academic health care system.
关于药剂师使用个人连续血糖监测仪（CGM）管理2型糖尿病（T2D）患者的影响，虽有证据，但有限且呈阳性。以往研究仅限于单诊所试点或样本量较小的社区药房。
评估由药剂师主导的创新型糖尿病管理与教育诊所（DMEC）使用个人CGM对T2D患者血糖结果的影响。
DMEC在一个大型三级学术医疗系统的初级保健机构开展工作，服务大量患者。药剂师根据合作实践协议，为初级保健和专科医疗提供者转诊的T2D患者提供护理管理。
利用CGM数据指导在DMEC看诊T2D患者的临床药剂师进行决策。
这是一项在DMEC进行了2年的回顾性研究。从电子病历中收集了在初次诊所就诊前已有个人CGM、就诊期间提供或作为处方订购的患者的人口统计学和血糖结果。完成了本研究的描述性分析。
DMEC药剂师使用CGM为165名患者指导治疗决策。初次就诊后3个月时，平均糖化血红蛋白下降了1.48%（P<0.001），6个月时下降了1.74%（P<0.001）。血糖达标时间在3个月时提高了8.2%（P<0.001），6个月时提高了12.1%（P<0.001）。血糖管理指标在3个月时下降了0.27%（P<0.001），6个月时下降了0.53%（P<0.001）。平均血糖在3个月时下降了13.5mg/dL（P<0.001），6个月时下降了18.8mg/dL（P<0.001）。
在大型学术医疗系统中，由药剂师主导使用个人CGM管理T2D可改善糖尿病治疗效果。
